249 related articles for article (PubMed ID: 33104024)
1. PET Amyloid and Tau Status Are Differently Affected by Patient Features.
Tan MS; Yang YX; Wang HF; Xu W; Tan CC; Zuo CT; Dong Q; Tan L; Yu JT;
J Alzheimers Dis; 2020; 78(3):1129-1136. PubMed ID: 33104024
[TBL] [Abstract][Full Text] [Related]
2. Association of amyloid-β CSF/PET discordance and tau load 5 years later.
Reimand J; Collij L; Scheltens P; Bouwman F; Ossenkoppele R;
Neurology; 2020 Nov; 95(19):e2648-e2657. PubMed ID: 32913020
[TBL] [Abstract][Full Text] [Related]
3. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
[TBL] [Abstract][Full Text] [Related]
4. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
Li QX; Villemagne VL; Doecke JD; Rembach A; Sarros S; Varghese S; McGlade A; Laughton KM; Pertile KK; Fowler CJ; Rumble RL; Trounson BO; Taddei K; Rainey-Smith SR; Laws SM; Robertson JS; Evered LA; Silbert B; Ellis KA; Rowe CC; Macaulay SL; Darby D; Martins RN; Ames D; Masters CL; Collins S;
J Alzheimers Dis; 2015; 48(1):175-87. PubMed ID: 26401938
[TBL] [Abstract][Full Text] [Related]
5. Discordant amyloid-β PET and CSF biomarkers and its clinical consequences.
de Wilde A; Reimand J; Teunissen CE; Zwan M; Windhorst AD; Boellaard R; van der Flier WM; Scheltens P; van Berckel BNM; Bouwman F; Ossenkoppele R
Alzheimers Res Ther; 2019 Sep; 11(1):78. PubMed ID: 31511058
[TBL] [Abstract][Full Text] [Related]
6. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
[TBL] [Abstract][Full Text] [Related]
7. PET and CSF amyloid-β status are differently predicted by patient features: information from discordant cases.
Reimand J; de Wilde A; Teunissen CE; Zwan M; Windhorst AD; Boellaard R; Barkhof F; van der Flier WM; Scheltens P; van Berckel BNM; Ossenkoppele R; Bouwman F
Alzheimers Res Ther; 2019 Dec; 11(1):100. PubMed ID: 31810489
[TBL] [Abstract][Full Text] [Related]
8. Florbetapir positron emission tomography and cerebrospinal fluid biomarkers.
Hake A; Trzepacz PT; Wang S; Yu P; Case M; Hochstetler H; Witte MM; Degenhardt EK; Dean RA;
Alzheimers Dement; 2015 Aug; 11(8):986-93. PubMed ID: 25916563
[TBL] [Abstract][Full Text] [Related]
9. CSF biomarkers and amyloid PET: concordance and diagnostic accuracy in a MCI cohort.
Spallazzi M; Barocco F; Michelini G; Immovilli P; Taga A; Morelli N; Ruffini L; Caffarra P
Acta Neurol Belg; 2019 Sep; 119(3):445-452. PubMed ID: 30847669
[TBL] [Abstract][Full Text] [Related]
10. Progression to dementia in memory clinic patients with mild cognitive impairment and normal β-amyloid.
Rosenberg A; Solomon A; Jelic V; Hagman G; Bogdanovic N; Kivipelto M
Alzheimers Res Ther; 2019 Dec; 11(1):99. PubMed ID: 31805990
[TBL] [Abstract][Full Text] [Related]
11. Clinic-Based Validation of Cerebrospinal Fluid Biomarkers with Florbetapir PET for Diagnosis of Dementia.
Álvarez I; Aguilar M; González JM; Ysamat M; Lorenzo-Bosquet C; Alonso A; Tartari JP; Romero S; Diez-Fairen M; Carcel M; Pujalte F; Pastor P
J Alzheimers Dis; 2018; 61(1):135-143. PubMed ID: 29154286
[TBL] [Abstract][Full Text] [Related]
12. The Cerebrospinal Fluid Aβ1-42/Aβ1-40 Ratio Improves Concordance with Amyloid-PET for Diagnosing Alzheimer's Disease in a Clinical Setting.
Niemantsverdriet E; Ottoy J; Somers C; De Roeck E; Struyfs H; Soetewey F; Verhaeghe J; Van den Bossche T; Van Mossevelde S; Goeman J; De Deyn PP; Mariën P; Versijpt J; Sleegers K; Van Broeckhoven C; Wyffels L; Albert A; Ceyssens S; Stroobants S; Staelens S; Bjerke M; Engelborghs S
J Alzheimers Dis; 2017; 60(2):561-576. PubMed ID: 28869470
[TBL] [Abstract][Full Text] [Related]
13. Concordance Between Different Amyloid Immunoassays and Visual Amyloid Positron Emission Tomographic Assessment.
Janelidze S; Pannee J; Mikulskis A; Chiao P; Zetterberg H; Blennow K; Hansson O
JAMA Neurol; 2017 Dec; 74(12):1492-1501. PubMed ID: 29114726
[TBL] [Abstract][Full Text] [Related]
14. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
[TBL] [Abstract][Full Text] [Related]
15. Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid β-amyloid 42: a cross-validation study against amyloid positron emission tomography.
Palmqvist S; Zetterberg H; Blennow K; Vestberg S; Andreasson U; Brooks DJ; Owenius R; Hägerström D; Wollmer P; Minthon L; Hansson O
JAMA Neurol; 2014 Oct; 71(10):1282-9. PubMed ID: 25155658
[TBL] [Abstract][Full Text] [Related]
16. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease.
Mattsson N; Cullen NC; Andreasson U; Zetterberg H; Blennow K
JAMA Neurol; 2019 Jul; 76(7):791-799. PubMed ID: 31009028
[TBL] [Abstract][Full Text] [Related]
17. Association between CSF Aβ42 and amyloid negativity in patients with different stage mild cognitive impairment.
He B; Wang L; Xu B; Zhang Y;
Neurosci Lett; 2021 May; 754():135765. PubMed ID: 33667602
[TBL] [Abstract][Full Text] [Related]
18. Testing the 2018 NIA-AA research framework in a retrospective large cohort of patients with cognitive impairment: from biological biomarkers to clinical syndromes.
Carandini T; Arighi A; Sacchi L; Fumagalli GG; Pietroboni AM; Ghezzi L; Colombi A; Scarioni M; Fenoglio C; De Riz MA; Marotta G; Scarpini E; Galimberti D
Alzheimers Res Ther; 2019 Oct; 11(1):84. PubMed ID: 31615545
[TBL] [Abstract][Full Text] [Related]
19. Amyloid cascade and tau pathology cerebrospinal fluid markers in mild cognitive impairment with regards to Alzheimer's disease cerebral metabolic signature.
Alexopoulos P; Guo LH; Jiang M; Bujo H; Grimmer T; Förster S; Drzezga A; Kurz A; Perneczky R
J Alzheimers Dis; 2013; 36(2):401-8. PubMed ID: 23609762
[TBL] [Abstract][Full Text] [Related]
20. Sex Differences in the Association of Global Amyloid and Regional Tau Deposition Measured by Positron Emission Tomography in Clinically Normal Older Adults.
Buckley RF; Mormino EC; Rabin JS; Hohman TJ; Landau S; Hanseeuw BJ; Jacobs HIL; Papp KV; Amariglio RE; Properzi MJ; Schultz AP; Kirn D; Scott MR; Hedden T; Farrell M; Price J; Chhatwal J; Rentz DM; Villemagne VL; Johnson KA; Sperling RA
JAMA Neurol; 2019 May; 76(5):542-551. PubMed ID: 30715078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
